دانلودمقاله باموضوع درمان کم خونی فقر آهن در CKD و مرحله پایانی بیماری کلیه
در قالب pdf و در 9 اسلاید،قابل ویرایش، شامل:
موضوع به انگلیسی:Treatment of Iron Deficiency Anemia in CKD
and End-Stage Kidney Disease
بخشی از متن:Iron deficiency is common in individuals with chronic kidney disease and plays a major role in the
development of anemia. Oral and intravenous iron agents are both available to replete iron in patients with
chronic kidney disease diagnosed with iron deficiency. The choice of which agent to use is most often
dictated by goals of therapy, tolerability, convenience, and response to prior therapy. Diminished absorption
of iron in the gastrointestinal tract and a high incidence of gastrointestinal adverse effects can
reduce the efficacy of oral iron agents, necessitating the use of i.v. iron formulations to treat iron deficiency
anemia, particularly in patients requiring kidney replacement therapy. Newer oral agents may help to
overcome these limitations and help treat iron deficiency in those not requiring kidney replacement
therapy. Recent studies have provided new evidence that more aggressive repletion of iron in patients
with chronic kidney disease requiring kidney replacement therapy may provide benefits with respect to
anemia management and hard clinical outcomes such as cardiovascular disease and survival.
